ABN Amro Investment Solutions Has $14.53 Million Stock Holdings in AbbVie Inc. $ABBV

ABN Amro Investment Solutions decreased its stake in AbbVie Inc. (NYSE:ABBV) by 7.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 62,756 shares of the company’s stock after selling 5,108 shares during the quarter. ABN Amro Investment Solutions’ holdings in AbbVie were worth $14,531,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Diversified Trust Co grew its stake in shares of AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after buying an additional 10,891 shares in the last quarter. Permanent Capital Management LP bought a new position in AbbVie during the third quarter valued at approximately $720,000. Railway Pension Investments Ltd lifted its stake in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after acquiring an additional 211,800 shares during the last quarter. World Investment Advisors grew its position in AbbVie by 9.4% in the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after acquiring an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co grew its position in AbbVie by 93.4% in the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after acquiring an additional 15,502 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Trading Up 1.8%

Shares of ABBV stock opened at $231.57 on Friday. The firm has a market capitalization of $409.28 billion, a P/E ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm’s fifty day simple moving average is $223.56 and its 200 day simple moving average is $220.85.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the firm earned $2.16 EPS. The business’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. BMO Capital Markets restated an “outperform” rating and set a $258.00 target price on shares of AbbVie in a report on Thursday, January 15th. Piper Sandler reiterated an “overweight” rating and set a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.